Company argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 12:55:00 2026-03-12 EDT			5-day change	1st Jan Change
616.00 ^EUR	-2.62%		-1.60%	-14.06%

03-11	Deutsche Bank Upgrades Argenx to Buy, Boosts PT	MT
03-06	Argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting	CI

Business description: argenx SE

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Number of employees: 1,599

Sales by Activity: argenx SE

Fiscal Period: December	2020 (EUR)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Biotechnology	54.53M	528M	441M	1.27B	2.25B

See all business segments

Geographical breakdown of sales: argenx SE

Fiscal Period: December	2020 (EUR)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	36.13M	317M	378M	1.08B	1.9B
Rest of The World	-	-	-	-	161M
Japan	-	-	15.76M	56.43M	89.39M
China	-	178M	4.24M	20.44M	43.52M
Netherlands	-	-	-	-	153K
EMEA	-	-	-	72.85M	-
Europe	-	-	5.68M	-	-
Other	-	123K	2.04M	-	-
Denmark	299K	1.39M	5.36M	-	-

See all geographic segments

Executive Committee: argenx SE

Manager	Title	Age	Since
Tim van Hauwermeiren CEO	Chief Executive Officer	54	2008-07-14
Karl Gubitz DFI	Director of Finance/CFO	56	2021-05-31
Filip Borgions CTO	Chief Tech/Sci/R&D Officer	-	2014-12-31
Karen Massey COO	Chief Operating Officer	47	2023-03-12
Peter Ulrichts CTO	Chief Tech/Sci/R&D Officer	46	2022-12-31

See ARGENX SE governance

Composition of the Board of Directors: argenx SE

Director	Title	Age	Since
Tim van Hauwermeiren BRD	Director/Board Member	54	2014-06-30
Peter K. M. Verhaeghe CHM	Chairman	68	2008-10-14
Joseph deBethizy BRD	Director/Board Member	76	2015-05-12
Pamela Klein BRD	Director/Board Member	65	2016-04-27
Anthony Adam Rosenberg BRD	Director/Board Member	72	2017-04-25
James Daly BRD	Director/Board Member	64	2018-05-07
Camilla Sylvest BRD	Director/Board Member	54	2022-09-07
Steve Krognes BRD	Director/Board Member	57	2023-02-26
Ana Cespedes BRD	Director/Board Member	53	2022-12-11
Brian Kotzin BRD	Director/Board Member	76	2024-05-06

Composition of the Board of Directors

Shareholders: argenx SE

Name	Equities	%	Valuation
Wellington Management Co. LLP 2.94 %	1,819,494	2.94 %	1 412 M €
Norges Bank Investment Management 2.813 %	1,740,588	2.813 %	1 351 M €
Sjunde AP-fonden 0.1429 %	88,442	0.1429 %	69 M €
State Street Global Advisors Ltd. 0.1232 %	76,270	0.1232 %	59 M €
Tim van Hauwermeiren 0.1165 %	72,095	0.1165 %	56 M €

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 9.037 %	5,592,319	9.037 %	4 289 M €
T. Rowe Price International Ltd. 5.433 %	3,362,324	5.433 %	2 579 M €
Janus Henderson Investors US LLC 3.972 %	2,458,164	3.972 %	1 885 M €
Capital Research & Management Co. (World Investors) 3.097 %	1,916,234	3.097 %	1 470 M €
Artisan Partners Holdings LP 2.839 %	1,756,942	2.839 %	1 347 M €

List of ARGENX SE shareholders

Company details: argenx SE

argenx SE

Laarderhoogtweg 25

1101 EB, Amsterdam

+31 10 703 8441

http://www.argen-x.com

Group companies: argenx SE

Name	Category and Sector
arGEN-X BV arGEN-X BV Pharmaceuticals: OtherHealth Technology Manufactures antibody-based medicines	Pharmaceuticals: Other
arGEN-X BV arGEN-X BV Pharmaceuticals: OtherHealth Technology Manufactures antibody-based medicines	Pharmaceuticals: Other

See all subsidiaries

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARGENX SE	-2.62%	-1.60%	+13.91%	+90.54%	44.8B
WUXI APPTEC CO., LTD.	-1.06%	-0.58%	+49.23%	+14.57%	40.35B
INSMED INCORPORATED	+0.09%	-2.82%	+88.44%	+675.97%	30.05B
BIONTECH SE	-0.81%	-11.62%	-10.18%	-29.31%	21.8B
WUXI BIOLOGICS (CAYMAN) INC.	+0.34%	-2.86%	+51.50%	-29.68%	19.09B
GENMAB A/S	-0.91%	-1.94%	+26.81%	-29.36%	16.72B
AKESO, INC.	-2.07%	+1.12%	+53.25%	+173.64%	13.53B
SUMMIT THERAPEUTICS INC.	-3.86%	+3.48%	-22.35%	+937.58%	12.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.93%	-0.10%	+62.10%	-	12.1B
EXELIXIS, INC.	-1.39%	-0.27%	+10.67%	+146.82%	10.84B
Average	-1.30%	+2.32%	+32.34%	+216.75%	22.17B
Weighted average by Cap.	-1.27%	+0.27%	+35.11%	+185.50%